Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
Alimentary Pharmacology & Therapeutics2017Vol. 47(4), pp. 485–493
Citations Over TimeTop 10% of 2017 papers
S. Tadbiri, Laurent Peyrin‐Biroulet, Mélanie Serrero, Jérôme Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stéfanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaut Vaysse, Anne Bourrier, Stéphane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Cyrielle Gilletta, Charlotte Gagnière, Lucine Vuitton, S Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Véred Abitbol, Mathurin Fuméry, P. Claudepierre, Yoram Bouhnik, Aurélien Amiot, the GETAID OBSERV‐IBD study group
Abstract
Vedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy.
Related Papers
- → Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety(2018)48 cited
- → The role of ultrasound in the diagnosis and follow-up of early inflammatory arthritis(2011)7 cited
- → Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab(2020)5 cited
- → Vedolizumab for the treatment of ulcerative colitis(2015)2 cited
- Differentiating Inflammatory Arthritis from Non-Inflammatory Arthritis in Patients with Knee Mono Arthritis Using IL-17(2015)